Ocugen(US:OCGN) Globenewswire·2025-10-23 11:30Core Insights - Ocugen, Inc. is set to host a conference call and live webcast on November 5, 2025, at 8:30 a.m. ET to discuss its third quarter 2025 financial results and provide a business update [1] - The company will issue a pre-market earnings announcement on the same day, with details for participation provided [2] - Ocugen is recognized as a leader in biotechnology, focusing on gene therapies for blindness diseases, utilizing a modifier gene therapy platform to address complex diseases caused by imbalances in multiple gene networks [3] Company Overview - Ocugen, Inc. specializes in gene therapies for blindness diseases, with a focus on inherited retinal diseases such as retinitis pigmentosa, Stargardt disease, and geographic atrophy [3] - The company's approach is gene-agnostic, aiming to meet significant unmet medical needs for large patient populations [3]